AstraZeneca Ends Phase III Lung Cancer Trial

AstraZeneca halted its Phase III trial of volrustomig combined with chemotherapy for metastatic non-small-cell lung cancer after an independent data monitoring committee concluded it was unlikely to meet the primary endpoints. Despite this setback, the company also reported a positive Phase III SAFFRON trial showing that Tagrisso plus Orpathys significantly improved progression-free and overall survival versus standard chemotherapy. AZN characterized the safety profile as consistent with known data and stated there were no new safety signals. The company intends to continue other late-stage volrustomig studies in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma, and will work with investigators to ensure continuity of care for enrolled patients. Market coverage notes that while the trial failure is a headwind, AZN maintains pipeline momentum and is pursuing a diversified immuno-oncology strategy. These updates collectively illustrate a mixed near-term picture for AstraZeneca’s lung-cancer portfolio with emphasis on its ongoing, potentially more promising combinations.